Literature DB >> 23218949

Simian-Human immunodeficiency viruses expressing chimeric subtype B/C Vpu proteins demonstrate the importance of the amino terminal and transmembrane domains in the rate of CD4(+) T cell loss in macaques.

Autumn Ruiz1, Kimberly Schmitt, Nathan Culley, Edward B Stephens.   

Abstract

Previously, we reported that simian-human immunodeficiency viruses expressing either the lab adapted subtype B (SHIV(KU-1bMC33)) or subtype C (SHIV(SCVpu)) Vpu proteins of human immunodeficiency virus type 1 (HIV-1) had different rates of CD4(+) T cell loss following inoculation into macaques. In this study, we have generated SHIVs that express either the subtype B or subtype C N-terminal (NTD) and transmembrane (TMD) domains and the opposing cytoplasmic domain (SHIV(VpuBC), SHIV(VpuCB)). In culture systems, SHIV(VpuBC) replicated faster than SHIV(VpuCB) while both proteins exhibited similar ability to down-modulate CD4 surface expression. Following inoculation into macaques, SHIV(VpuBC) resulted in rapid CD4(+) T cell loss similar to the parental SHIV(KU-1bMC33), while the rate of CD4(+) T cell loss in those inoculated with SHIV(VpuCB) was intermediate of SHIV(SCVpu) and SHIV(KU-1bMC33). These results emphasize the importance of the Vpu NTD/TMD region in the rate of CD4(+) T cell loss in the pathogenic X4 SHIV/macaque model.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23218949      PMCID: PMC4104993          DOI: 10.1016/j.virol.2012.10.030

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  49 in total

1.  Rapid degradation of CD4 in cells expressing human immunodeficiency virus type 1 Env and Vpu is blocked by proteasome inhibitors.

Authors:  K Fujita; S Omura; J Silver
Journal:  J Gen Virol       Date:  1997-03       Impact factor: 3.891

2.  Subtype C Is associated with increased vaginal shedding of HIV-1.

Authors:  Grace C John-Stewart; Ruth W Nduati; Christine M Rousseau; Dorothy A Mbori-Ngacha; Barbra A Richardson; Stephanie Rainwater; Dana D Panteleeff; Julie Overbaugh
Journal:  J Infect Dis       Date:  2005-06-23       Impact factor: 5.226

3.  Deletion of the vpu sequences prior to the env in a simian-human immunodeficiency virus results in enhanced Env precursor synthesis but is less pathogenic for pig-tailed macaques.

Authors:  Edward B Stephens; Coleen McCormick; Erik Pacyniak; Darcy Griffin; David M Pinson; Francis Sun; Warren Nothnick; Scott W Wong; Robert Gunderson; Nancy E J Berman; Dinesh K Singh
Journal:  Virology       Date:  2002-02-15       Impact factor: 3.616

4.  Some human immunodeficiency virus type 1 Vpu proteins are able to antagonize macaque BST-2 in vitro and in vivo: Vpu-negative simian-human immunodeficiency viruses are attenuated in vivo.

Authors:  Masashi Shingai; Takeshi Yoshida; Malcolm A Martin; Klaus Strebel
Journal:  J Virol       Date:  2011-07-20       Impact factor: 5.103

5.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

6.  Requirements of the membrane proximal tyrosine and dileucine-based sorting signals for efficient transport of the subtype C Vpu protein to the plasma membrane and in virus release.

Authors:  Autumn Ruiz; M Sarah Hill; Kimberly Schmitt; John Guatelli; Edward B Stephens
Journal:  Virology       Date:  2008-06-24       Impact factor: 3.616

7.  Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains.

Authors:  Daniel Sauter; Michael Schindler; Anke Specht; Wilmina N Landford; Jan Münch; Kyeong-Ae Kim; Jörg Votteler; Ulrich Schubert; Frederic Bibollet-Ruche; Brandon F Keele; Jun Takehisa; Yudelca Ogando; Christina Ochsenbauer; John C Kappes; Ahidjo Ayouba; Martine Peeters; Gerald H Learn; George Shaw; Paul M Sharp; Paul Bieniasz; Beatrice H Hahn; Theodora Hatziioannou; Frank Kirchhoff
Journal:  Cell Host Microbe       Date:  2009-11-19       Impact factor: 21.023

8.  Suppression of Tetherin-restricting activity upon human immunodeficiency virus type 1 particle release correlates with localization of Vpu in the trans-Golgi network.

Authors:  Mathieu Dubé; Bibhuti Bhusan Roy; Pierre Guiot-Guillain; Johanne Mercier; Julie Binette; Grace Leung; Eric A Cohen
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

9.  A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.

Authors:  Tonya Kueck; Stuart J D Neil
Journal:  PLoS Pathog       Date:  2012-03-29       Impact factor: 6.823

10.  Identification of Residues in the BST-2 TM Domain Important for Antagonism by HIV-1 Vpu Using a Gain-of-Function Approach.

Authors:  Takeshi Yoshida; Sandra Kao; Klaus Strebel
Journal:  Front Microbiol       Date:  2011-02-18       Impact factor: 5.640

View more
  3 in total

1.  A comparative mutational analysis of HIV-1 Vpu subtypes B and C for the identification of determinants required to counteract BST-2/Tetherin and enhance viral egress.

Authors:  Janet L Douglas; Ying Bai; Jean K Gustin; Ashlee V Moses
Journal:  Virology       Date:  2013-04-10       Impact factor: 3.616

2.  Involvement of a C-terminal motif in the interference of primate lentiviral Vpu proteins with CD1d-mediated antigen presentation.

Authors:  Susanna M Bächle; Daniel Sauter; Sabrina Sibitz; Johan K Sandberg; Frank Kirchhoff; Markus Moll
Journal:  Sci Rep       Date:  2015-04-15       Impact factor: 4.379

3.  The Envelope Cytoplasmic Tail of HIV-1 Subtype C Contributes to Poor Replication Capacity through Low Viral Infectivity and Cell-to-Cell Transmission.

Authors:  Eveline Santos da Silva; Martin Mulinge; Morgane Lemaire; Cécile Masquelier; Cyprien Beraud; Arkadiusz Rybicki; Jean-Yves Servais; Gilles Iserentant; Jean-Claude Schmit; Carole Seguin-Devaux; Danielle Perez Bercoff
Journal:  PLoS One       Date:  2016-09-06       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.